Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
A live webcast of the fireside chat will be made available under in the Investors section of the and will be archived for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
View source version on businesswire.com:
Media
Corporate Communications, Vir Biotechnology
[email protected]
Investors
Richard Lepke
Senior Director, Investor Relations
[email protected]
Source: Vir Biotechnology, Inc.
